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A B S T R A C T
During pregnancy, the fetus requires nutrients supplied by the mother to grow and develop. However, the
mother also requires sufficient resources to support the pregnancy, as well as, to maintain her health. Fail-
ure to regulate resource allocation between the mother and fetus can lead to pregnancy complications with
immediate and life-long consequences for maternal and offspring health. This review explores the role of in-
sulin-like growth factor (IGF)-2 in regulating materno-fetal resource allocation, particularly via its regulation
of placental development and function.
© 2017.
1. Introduction
For a successful pregnancy outcome, nutrients must be partitioned
correctly between the fetus for growth and development, and the
mother to maintain the pregnancy and support lactation. Failure to
achieve this nutrient balance can lead to pregnancy complications,
such as abnormal birth weight and gestational diabetes. Combined,
these complications affect >12% of pregnancies in developed nations
like the UK [1] and are associated with immediate and life-long conse-
quences for health of the mother and child. Altered nutrient and oxy-
gen supply in utero leads to permanent changes in the development
and function of individual fetal organs, and is associated with car-
diovascular and metabolic dysfunction in offspring in later life [2,3].
In addition, maternal metabolic mal-adaptations during pregnancy can
compromise the success of future pregnancies, and increase the risk
of metabolic diseases, such as type 2 diabetes in the mother in later
life [4]. Thus, understanding the mechanisms governing maternal-fetal
resource allocation is important for pregnancy success and life-long
health of both the mother and baby.
The main determinant of resource allocation during pregnancy is
the placenta. It constitutes the interface between the mother and fetus
Abbreviations: IGF, insulin-like growth factor; IGF1R, type 1 IGF receptor;
IGF2R, type 2 IGF receptor; IGFBP, IGF binding protein; INSR, insulin receptor;
Jz, junctional zone; Lz, labyrinthine zone; PI3K, phosphoinositol 3-kinase
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that controls nutrient and oxygen transfer. The placenta responds to
nutritional and metabolic signals in the mother by altering its structure
and function and, thereby, appears to link maternal perturbations to
changes in fetal resource supply and growth [5,6]. However, the pla-
centa is not a passive organ; it is also able to adapt its transport capac-
ity in response to fetal nutrient demand signals, as well as, to maternal
signals of nutrient availability, thereby ensuring optimal allocation of
available resources [5–8]. Moreover, the placenta signals fetal needs
to the mother, via its secretion of hormones which affect maternal me-
tabolism and thus, the supply of nutrients for fetal growth [5]. This re-
view examines the role of the fetal growth factor, insulin-like growth
factor (IGF)-2 in controlling materno-fetal resource allocation, partic-
ularly via its modulation of placental phenotype. The data discussed
are largely from mice; a recently published review highlights the role
of IGF2 in placental resource allocation in additional species, includ-
ing the human [9].
The mouse, like the human, displays an invasive, haemochorial
placenta that forms under similar genetic control [10]. However, there
are a few differences between mice and humans that should be noted.
In mice, the function of the yolk sac placenta persists until term
and the placental exchange interface is labyrinthine rather than vil-
lous, compared to human. In mice, there is a distinct endocrine junc-
tional zone, which is not present in the human placenta and there
are differences in the types of hormones expressed between the two
species [11,12]. Moreover, the mouse is a litter bearing species and
the level of constraint on the mother to provide resources during
pregnancy may be higher than in humans that normally have one
https://doi.org/10.1016/j.placenta.2018.01.005
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baby [13]. However, both genetic and environmental manipulations
have been undertaken in mice, which are beneficial in providing in-
sight into the mechanisms governing materno-fetal resource allocation
in mammals.
1.1. Insulin-like growth factor-2 (IGF2)
IGF2 is a small (∼7.5kDa) anabolic polypeptide that binds to three
cell surface receptors: the type 2 IGF receptor (IGF2R), the type 1
IGF receptor (IGF1R) and the insulin receptor (INSR), with decreas-
ing affinity [14]. The mitogenic, pro-survival and metabolic actions
of IGF2 are thought to be principally mediated through binding to the
IGF1R, which leads to activation of the phosphoinositide-3 kinase/
protein kinase A (PI3K/AKT) and mitogen-activated protein kinase
(MAPK) signalling pathways [9]. In contrast, interaction of IGF2 with
IGF2R results in its internalisation and degradation or activation of
G-protein-coupled signalling [15]. Although, the specific conditions
that determine whether IGF2 binding to the IGF2R results in its degra-
dation or signalling, require elucidation. A family of binding proteins
(IGFBPs) and IGF-related binding proteins modulate the accessibility
of IGF2 to its receptors [9].
Expression of the Igf2 gene is controlled by parental imprinting,
with only the paternal allele expressed in the mouse [16]. The Igf2
gene has multiple promoters, from which a transcript specific to the
placenta, Igf2P0, originates in mice [17]. Recent work has shown
this is due the repression of the Igf2P0 transcript in the embryo by a
zinc-finger protein, ZFP568 [18]. There is also evidence that the tran-
scription factor, Zac1, regulates Igf2 transcript expression in mice dur-
ing prenatal development [19]. Multiple antisense transcripts for the
Igf2 gene (Igf2as) have also been reported to expressed in mice, albeit
from the complementary DNA strand [17].
1.2. IGF2 expression at the feto-maternal interface
Components of the IGF2 system are expressed by the mouse con-
ceptus during the early stages of development (Fig. 1). IGF2 is ex-
pressed from the 2-cell stage [20], and by implantation (∼day 4 of
gestation), it is co-localised with IGF1R and/or IGF2R in the cell lin-
eages that will go on to form the fetus and placenta [21–23]. In par-
ticular, from day 5.5–6.5, IGF2 and IGF1R are abundantly expressed
in the developing embryo, the extraembryonic ectoderm, and the ec-
toplacental cone [22]. Transcripts for Igf2 and its receptors are also
detected in the yolk sac placenta on day 9.5 of gestation [24]. Later,
when the definitive mouse placenta is formed (∼day 10 of gestation),
IGF2 and IGF1R are expressed by the syncytiotrophoblast in the trans-
port labyrinthine zone (Lz) and enriched in the glycogen cells in the
endocrine junctional zone (Jz), although they are also present in the
spongiotrophoblast and giant cells [25,26]. Particularly during vascu-
larisation, IGF2 is highly expressed by the chorionic mesoderm and
Lz fetal vessels [25,27]. IGF2 is also abundantly expressed by the en-
doderm and mesoderm of the yolk sac placenta at day 12.5 of gesta-
tion [27]. The Igf2P0 transcript appears to be specifically expressed
by cell lineages in the Lz, at least at day 12 of pregnancy [28]. Igf2as
transcripts have been detected during the early stages of embryonic
development, although their spatial expression in the definitive pla-
centa and yolk sac remains to be determined [24,29]. IGF2R is also ex-
pressed by the embryo and trophoblast cell lineages post-implantation
[23]. However, at around day 10.5, IGF2R expression appears to be
mainly confined to the vasculature in the Lz, and trophoblast lineages
in the Jz [22,26]. INSR is also expressed by the mouse placenta and
yolk sac in early and/or the late stages of development [23,24,30], al-
though its specific localisation is unknown. The IGFBPs are predom-
inantly expressed by the decidua, although lower expression levels of
specific IGFBPs have been reported for the chorionic mesoderm, Lz,
Jz and yolk sac placenta [24,27,31,32]. Combined, these data suggest
that IGF2 may interact with IGF2R to drive Lz vascularisation, IGF1R
to promote formation and function of the syncytiotrophoblast and both
IGF receptors to control Jz differentiation and yolk sac function during
mouse development. Moreover, such interactions may be fine-tuned
by the IGFBPs.
1.3. IGF2 and its importance for feto-placental phenotype and
resource allocation
Genetic studies in mice have supported the important role of IGF2
as a fetal growth factor via its direct anabolic actions within the fe-
tus, and by its modulation of placental supply capacity (Fig. 2). For
instance, Igf2 over-expression causes placental and fetal overgrowth
[33], whereas Igf2 gene deletion reduces feto-placental weight from
early in gestation [34,35]. These changes relate to alterations in pla-
cental Lz (composition, surface area and/or barrier thickness; which
determine nutrient and/or oxygen transfer) and Jz formation (glyco-
gen cells), and a decrease in placental nutrient transport, passive per-
meability and supply efficiency [33,36–40]. Deleting the Lz-exclu-
sive Igf2P0 transcript in mice, which leaves the other placental tran-
scripts and fetal expression of Igf2 intact, also impairs growth of
both placental zones from early in development, and reduces the
passive permeability of the placenta, as well as, fetal
Fig. 1. Expression of IGF2 and the receptors it can bind by the mouse conceptus during development. Data shown for day 14 of pregnancy are inferred from studies performed on
samples collected from days 10.5 until day 18.5 of pregnancy. E, embryo; EPC, ectoplacental cone; ExE, extraembryonic mesenchyme; FC, fetal capillaries; GiT, giant cells, GlyT,
glycogen cells, SpT, spongiotrophoblast; Lz, labyrinthine zone. Data are from Refs. [20–23,25–28]. Note, IGF2 is also abundantly expressed by the endoderm and mesoderm of the
yolk sac during gestation.
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Fig. 2. Impact of genetically manipulating the expression of Igf2 on fetal growth and placental development and transport function. AA, amino acid; BT, interhaemal membrane
barrier thickness (inversely related to the diffusion of molecules like oxygen), FC, fetal capillaries; Glu, glucose; GlyT, glycogen cells; Lz, labyrinthine zone; MBS, maternal blood
spaces; SA, surface area; T, trophoblast. Data are from Refs. [28,33,37–41].
growth [28,39]. As the Igf2P0 transcript accounts for ∼10% of total
Igf2 transcripts in the mature mouse placenta [28], these findings high-
light that the Igf2P0 transcript plays a disproportionately important
role in promoting fetal and placental growth.
The Igf2P0 deficient placenta also adapts its nutrient transport
characteristics to help maintain fetal growth. Fetal growth is not re-
stricted until late gestation and to a lesser extent as predicted by the
reduced size and passive permeability of the Igf2P0 null [28,37]. This
is because the Igf2P0 null placenta is able to partially compensate for
these defects by up-regulating its capacity for glucose, amino acid and
calcium transport during pregnancy [28,41,42]. This increase in pla-
cental supply efficiency is associated with enhanced expression of glu-
cose and System A amino acid transporters, as well as, the intracellu-
lar calcium-binding protein, calbindin-D9K by the Igf2P0 mutant pla-
centa. Adaptations in glucose and amino acid transport, however, do
not occur in the complete Igf2 null that lacks both placental and fetal
Igf2 [37]. The impact of Igf2 deficiency on the capacity of the yolk
sac to provide maternal nutrients for fetal growth, although, remains to
be explored. Genetic manipulation of Igf1r, Igf2r and Insr also affects
feto-placental phenotype, which has previously been summarised [9].
Taken together, these data emphasize an interplay between placental
Igf2 transcripts and fetal IGF2 in regulating placental nutrient alloca-
tion to the fetus. The available data also suggest that IGF2 may play
a role, directly or indirectly, in adapting placental transport capacity
during development.
1.4. IGF2 in the environmental modulation of placental resource
supply to fetal growth
Mechanisms adapting placental transport capacity are likely to be
particularly important when maternal conditions are not favourable
for fetal nutrient supply. Undernutrition during pregnancy is com-
mon in many developing countries and is the main cause of preg-
nancy complications such as low birth weight [43]. In mice, under-
nutrition (20% reduction in food intake from day 3 of pregnancy)
leads to a down-regulation of Igf2P0 expression and PI3K signalling
in association with reduced placental weight in early gestation [43,44].
However, fetal growth is only restricted just prior to term in un-
dernourished dams [43]. Fetal growth is preserved until this time
through the maintenance of Lz formation in early pregnancy, and an
adaptive up-regulation of amino acid transport in late gestation by the
growth restricted, undernourished wildtype placenta [43]. These adap-
tations depend on Igf2P0 expression by the undernourished placenta,
as Lz development is defective from early in gestation and there is
no adaptive increase in amino acid transport near term in the small
Igf2P0 deficient placenta in response to maternal undernutrition [44].
The morphological and functional failure of the Igf2P0 null placenta
to adapt to undernutrition, results in an earlier onset and more severe
reduction in fetal size, as compared to that seen with the wildtype pla-
centa. Thus, the data suggest that the placental-specific transcript of
the Igf2 gene is involved in placental adaptations to undernutrition.
IGF2 may also play a role in the adaptation of placental resource
supply in pregnancies challenged by an obesogenic diet. In many de-
veloped countries, women of reproductive age obtain a high propor-
tion of their energy intake from fat and/or sugar [30]. These dietary
habits contribute to the increasing number of women who gain excess
weight and develop gestational diabetes during pregnancy. In mice,
the consumption of an obesogenic diet containing high sugar and high
fat (5-times sugar and 3-times fat of control chow; HSHF) from day 1
of pregnancy compromises maternal insulin sensitivity, glucose toler-
ance and glucose production [45]. Furthermore, fetal growth, placen-
tal size and Lz development is reduced in early gestation by a HSHF
diet [30]. However, by term, fetal weights are no longer reduced, de-
spite the placenta remaining small and morphologically defective [30].
The normalisation of fetal growth in late gestation is associated with
an up-regulation of glucose and amino acid transfer by the placenta to
the fetus in HSHF dams earlier in pregnancy [30]. This increase in pla-
cental supply capacity is coupled with an enhanced expression of the
System A amino acid transporter, Slc38a2, and glucose transporter,
Slc2a3. It is also associated with an increase in Igf2P0 transcript ex-
pression and PI3K signalling in the placenta of dams fed the HSHF
diet. Collectively, these data suggest that in response to an obesogenic
diet that disrupts maternal metabolism, the placenta adapts its pheno-
type to help meet fetal nutrient demands for growth near term. More-
over, these adaptations are associated with changes in IGF2 signalling
in the placenta.
Recent evidence suggests that IGF2 signalling may also be in-
volved in altering placental supply capacity in response to hypoxia
during pregnancy. Hypoxia is a common feature of compromised
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human pregnancies at sea level with adverse outcomes for the infant.
Moreover, hypoxia is a major cause of fetal growth restriction in preg-
nancies at high altitude [46]. In mice, reducing maternal inspired oxy-
gen to 13% for five days prior to term, leads to an increase in placental
Igf2P0 expression and PI3K signalling in association with greater Lz
vascular density, a thinner barrier to diffusion of molecules like oxy-
gen, increased glucose transport and only a marginal (5%) reduction
in fetal growth [46]. In contrast, reducing maternal inspired oxygen to
10% for the same duration does not induce beneficial changes in pla-
cental Igf2P0 expression and PI3K signalling, nor lead to an increase
in Lz vascularisation or glucose transport. In contrast, 10% hypoxia
results in a thicker trophoblast barrier to diffusion, diminished placen-
tal amino acid transport, and a four times greater reduction (21%) in
fetal growth [46]. Taken together, these data suggest that there is a
threshold between 13% and 10% maternal inspired oxygen, at which
the placenta can no longer optimise fetal nutrient and oxygen supply
and fetal growth in late pregnancy. Furthermore, changes in placental
supply capacity with hypoxia appear to relate to the level of IGF2 sig-
nalling in the placenta.
Similar relationships between IGF2 signalling and placental sup-
ply capacity have been reported in response to other maternal chal-
lenges that affect conceptus development [9]. For instance, elevating
the concentration of the stress hormone, corticosterone in mouse dams
in late pregnancy diminishes placental PI3K signalling and compro-
mises placental size, Lz morphology, amino acid supply capacity and
fetal growth [47,48].
Taken together, the available data demonstrate that an environmen-
tal challenge, which affects the ability of the mother to provide nu-
trients and oxygen to fetal growth, is associated with changes in pla-
cental IGF2 signalling, morphology and functional capacity (Table
1). Moreover, the timing, nature and type of challenge during preg-
nancy determine the specific placental response elicited. However,
irrespective of the insult, whenever placental resource allocation is
altered, there is a change in IGF2 signalling in the placenta (Table
1). Thus, IGF2 appears to act as an environmental sensor, driving
changes in placental phenotype to optimise the allocation of resources
in the prevailing environment [9]. However, functional studies com-
bining environmental and genetic manipulations in mice
Table 1
A summary of the impact of maternal environmental manipulations on placental pheno-
type and fetal weight in mice.
Maternal challenge
Undernutrition
Obesogenic
diet
13%
hypoxia
10%
hypoxia
Excess
corticosterone
Placental Lz
development
Initially
preserved
↓ late in
gestation
↓ ↑ ↓ ↓
Placental
transport
↑ AA ↑ AA &
glucose
↓ oxygen
↑
glucose
&
oxygen
↓ AA &
oxygen
↓ AA
Placental
IGF2–PI3K
signalling
↓a ↑ ↑ ↓ ↓
Fetal weight ↔ early in
gestation
↓ 14% late in
gestation
↓ 10% early
in
gestation
↔ late in
gestation
↓ 5% ↓ 21% ↓ 20%
a Igf2P0 required for the structural and functional adaptations to maternal
undernutrition. Data are from Refs. [30,44,46–48]. Oxygen transfer is inferred from the
interhaemal membrane barrier thickness. AA, amino acid.
are needed to more precisely determine the casual relationships be-
tween changes in placental IGF2, resource allocation and fetal growth
(as done previously for undernutrition and the Igf2P0 null [44]). Fu-
ture studies are also required to identify the mechanisms by which Igf2
expression by the placenta may be modified by the gestational envi-
ronment.
1.5. Maternal versus fetal signalling in the regulation of placental
resource allocation
IGF2 is not only highly expressed in the placenta, but is abundant
in the fetal and maternal circulation during mouse pregnancy [49,50].
Thus, adaptations in placental resource allocation may also be driven
by IGF2 signalling in the fetus or the mother, or both. In adult tissues,
the PI3K catalytic isoform, p110α is largely responsible for mediating
the metabolic effects of anabolic hormones, like IGF2 [51]. Studies
in mice using genetic manipulation of p110α have therefore, started
to provide insight into the role of signalling in the fetus versus in the
mother, in determining specific placental phenotypes. In mice, geneti-
cally inactivating p110α activity by 50% (p110αD933A/+; α/+) in the fe-
tus, reduces placental size and Lz formation (decreases in Lz vascular-
isation, surface area and an increase in the barrier to diffusion), in as-
sociation with impaired fetal growth [52]. However, despite the com-
promised morphology, the placenta adapts functionally by increasing
the supply of glucose and amino acid to the fetus in α/+ mutants. This
increase in placental supply capacity is more pronounced near term
and relates to an improved growth trajectory of α/+ fetuses when com-
pared with wildtypes. These data suggest functional adaptation of pla-
cental nutrient allocation in response to a deficiency in fetal p110α sig-
nalling.
Placental resource allocation also responds to a deficiency of
p110α signalling in the mother. In α/+ mouse dams, placental weight
and Lz formation is increased (larger surface area and reduced barrier
to diffusion, depending on the gestational age) although the placenta
transports less glucose to the fetus and fetal weight is unaffected by
the maternal genotype during pregnancy [52]. These maternally-dri-
ven alterations in placental phenotype appear to be related to the re-
duced size and altered metabolic and endocrine milieu of the α/+ dam
during pregnancy [52]. Hence, there is adaptation of the placenta to
match the supply capacity of the dam with a deficiency in p110α sig-
nalling. Overall, the data therefore suggest that placental resource al-
location adapts in response to changes in IGF2 signalling capacity in
both the fetus and mother. However, caution is warranted as little is
known about the abundance of the IGF2 system components in the α/+
fetuses or dams. There is also no information available on the path-
ways that may compensate to improve placental transport capacity in
the α/+ conceptuses. Such signalling pathways include the mechanis-
tic target of rapamycin, general control nonrepressed 2, G-protein cou-
pled-receptors and adenosine monophosphate-activated protein kinase
which have been implicated in environmental sensing [53,54] and may
drive alterations in placental transport phenotype in response to IGF2/
p110α signalling deficiency.
1.6. Role of IGF2 in placental endocrine regulation of maternal
resource allocation to the fetus
As previously mentioned, the placenta secretes hormones that af-
fect the availability of nutrients in the mother for fetal growth. More-
over, IGF2 is important for the formation and function of endocrine
cells in the mouse placenta (Fig. 2). It is therefore plausible that via
its modulation of placental endocrine capacity, IGF2 may be involved
in signalling to the mother to alter her provision of nutrients for the
UN
CO
RR
EC
TE
D
PR
OO
F
Placenta xxx (2018) xxx-xxx 5
fetus. Studies of wildtype dams carrying Igf2 mutant conceptuses sup-
ports this notion. For instance, dams carrying pups with Igf2 over-ex-
pression show increased glucose concentrations during pregnancy
[55]. Furthermore, dams carrying litters of Igf2P0 nulls show in-
creased circulating glucose, insulin, leptin and/or corticosterone con-
centrations in fed and undernourished conditions [44]. Studies selec-
tively modulating the expression of Igf2 in placental endocrine cells
are although warranted to specifically address the role of IGF2 in pla-
cental endocrine regulation of maternal-fetal nutrient allocation.
2. Summary and conclusions
In mice, IGF2 is important for controlling placental resource al-
location to fetal growth via its actions on placental formation, nu-
trient transport and endocrine capacity during development, as well
as, in response to environmental challenges (Fig. 3). Moreover, via
the IGF2 signalling pathway, the placenta is able to fine-tune the
supply of maternal resources to the fetus in accordance with both
the fetal drive for growth and the maternal ability to supply the re-
quired nutrients during pregnancy. In human pregnancy, IGF2 is pre-
sent in both the fetal and maternal circulations and the IGF2 system
is widely expressed by the placenta [9,56]. It promotes the prolifera-
tion, differentiation, survival and uptake of nutrients by cultured hu-
man trophoblast and the abundance of the IGF2 system is altered in
the placenta from women with poor environmental conditions (un-
balanced dietary intakes, obesity, increased cortisol, residence at high
altitude) and/or abnormal fetal growth during pregnancy (reviewed
previously [9,56]). Therefore, IGF2 may play a similar regulatory role
in controlling placental resource allocation during human pregnancy.
By understanding the role of IGF2 in regulating the allocation of re-
sources between the mother and fetus during pregnancy, the work
discussed may provide novel insight into the aetiology of pregnancy
complications and programming mechanisms.
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Fig. 3. The role of IGF2 signalling in the placenta and its importance for the allocation of resources between the mother and the fetus for growth.
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